AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways
Authors
Keywords
Src, EGFR, NSCLC, AC-93253 iodide, Gefitinib
Journal
Journal of Hematology & Oncology
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-11-13
DOI
10.1186/s13045-017-0539-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II Consortium
- (2017) L. Wiebe et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
- (2016) Yongkun Sun et al. Journal of Hematology & Oncology
- Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
- (2016) Shuhang Wang et al. Journal of Hematology & Oncology
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- A Pooled Analysis on Crizotinib in Treating Chinese Patients with EML4-ALK Positive Non-small-cell Lung Cancer
- (2015) Yang Li et al. Asian Pacific Journal of Cancer Prevention
- AC-93253 triggers the downregulation of melanoma progression markers and the inhibition of melanoma cell proliferation
- (2015) Iwona Karwaciak et al. CHEMICO-BIOLOGICAL INTERACTIONS
- Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways
- (2015) Yi-Hua Lai et al. Oncotarget
- Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status
- (2015) Luigi Formisano et al. Oncotarget
- Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
- (2014) G Peiró et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2014
- (2014) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer
- (2014) Nobuaki Ochi et al. EXPERIMENTAL CELL RESEARCH
- A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer
- (2014) K. A. Gold et al. ONCOLOGIST
- Ubiquitin-proteasome system, a new anti-tumor target
- (2013) Wei Du et al. ACTA PHARMACOLOGICA SINICA
- The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets
- (2013) Steven L. Wood et al. CANCER TREATMENT REVIEWS
- The HLJ1 -targeting drug screening identified Chinese herb andrographolide that can suppress tumour growth and invasion in non-small-cell lung cancer
- (2013) Yi-Hua Lai et al. CARCINOGENESIS
- Cellular Functions Regulated by Phosphorylation of EGFR on Tyr845
- (2013) Ken-ichi Sato INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- A Novel Function of YWHAZ/ -Catenin Axis in Promoting Epithelial-Mesenchymal Transition and Lung Cancer Metastasis
- (2012) C.-H. Chen et al. MOLECULAR CANCER RESEARCH
- Dimethyl Sulfoxide Promotes the Multiple Functions of the Tumor Suppressor HLJ1 through Activator Protein-1 Activation in NSCLC Cells
- (2012) Chi-Chung Wang et al. PLoS One
- Polypharmacology: drug discovery for the future
- (2012) A Srinivas Reddy et al. Expert Review of Clinical Pharmacology
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
- (2011) L. V. Sequist et al. ANNALS OF ONCOLOGY
- Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells
- (2011) Lori Rice et al. CLINICAL & EXPERIMENTAL METASTASIS
- Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib
- (2011) Melissa L. Johnson et al. Journal of Thoracic Oncology
- Targeting Src family kinases in anti-cancer therapies: turning promise into triumph
- (2011) Siyuan Zhang et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Phase I/II Study of the Src Inhibitor Dasatinib in Combination With Erlotinib in Advanced Non–Small-Cell Lung Cancer
- (2010) Eric B. Haura et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity
- (2009) Yingjia Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Recent advances in computer-aided drug design
- (2009) C. M. Song et al. BRIEFINGS IN BIOINFORMATICS
- Improved Response by Co-targeting EGFR/EGFRvIII and Src Family Kinases in Human Cancer Cells
- (2009) Peter Andersen et al. CANCER INVESTIGATION
- Intestinal epithelial cancer cell anoikis resistance: EGFR-mediated sustained activation of Src overrides Fak-dependent signaling to MEK/Erk and/or PI3-K/Akt-1
- (2009) Marie-Josée Demers et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Src Promotes Survival and Invasion of Lung Cancers with Epidermal Growth Factor Receptor Abnormalities and Is a Potential Candidate for Molecular-Targeted Therapy
- (2009) E. L.-H. Leung et al. MOLECULAR CANCER RESEARCH
- Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin
- (2009) P. Ceppi et al. MOLECULAR CANCER THERAPEUTICS
- Src kinases as therapeutic targets for cancer
- (2009) Lori C. Kim et al. Nature Reviews Clinical Oncology
- Mechanisms of drug combinations: interaction and network perspectives
- (2009) Jia Jia et al. NATURE REVIEWS DRUG DISCOVERY
- The role of cooperativity with Src in oncogenic transformation mediated by non-small cell lung cancer-associated EGF receptor mutants
- (2009) B M Chung et al. ONCOGENE
- The Role of Src in Solid Tumors
- (2009) D. L. Wheeler et al. ONCOLOGIST
- Targeting Src in breast cancer
- (2008) R. S. Finn ANNALS OF ONCOLOGY
- The SIRT2 Deacetylase Regulates Autoacetylation of p300
- (2008) Joshua C. Black et al. MOLECULAR CELL
- Somatic mutations affect key pathways in lung adenocarcinoma
- (2008) Li Ding et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search